AARTI PHARMALABS LIMITED vs DIVI S LABORATORIES LTD

A side-by-side comparison of AARTI PHARMALABS LIMITED (AARTIPHARM) and DIVI S LABORATORIES LTD (DIVISLAB) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads AARTIPHARM vs DIVISLAB on 12 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

36.74
P/E ratio
74.93
2.98
P/B ratio
10.72
0.21%
Dividend yield
0.44%
₹19.27
EPS
₹96.73

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

8.59%
Return on equity
16.50%
11.00%
Return on capital
22.00%
20.00%
EBITDA margin
33.00%
9.62%
Net margin
24.32%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

-2.21%
Revenue CAGR (3Y)
10.78%
-3.21%
Profit CAGR (3Y)
12.10%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹6,409 Cr
Market cap
₹1.92L Cr
₹1,819 Cr
Revenue
₹10,560 Cr
₹175 Cr
Net profit
₹2,568 Cr
0.35
Debt / equity
0.00
AARTI PHARMALABS LIMITED
  • ["Stock is trading at 3.03 times its book value", "Company has a low return on equity of 11.9% over last 3 years."]
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 10.8 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
AARTI PHARMALABS LIMITED full analysis DIVI S LABORATORIES LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.